The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
Open accessAbstract
Summary Background Dengue virus is the most serious mosquito-borne viral threat to public health and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent DENVax vaccine contains a molecularly characterised live attenuated dengue serotype-2 virus (DENVax-2) and three recombinant vaccine viruses expressing the prM and E structural genes for serotypes 1, 3, and 4 in the DENVax-2 genetic backbone. We aimed to assess the safety and immunogenicity of tetravalent DENVax formulations. Methods We undertook a randomised, double-blind, phase 1, dose-escalation trial between Oct 11, 2011, and Nov 9, 2011, in the Rionegro, Antioquia, Colombia. The first cohort of participants (aged 18–45 years) were randomly assigned centrally, via block randomisation, to receive a low-dose formulation of DENvax, or placebo, by either subcutaneous or intradermal administration. After a safety assessment, participants were randomly assigned to receive a high-dose DENVax formulation, or placebo, by subcutaneous or intradermal administration. Group assignment was not masked from study pharmacists, but allocation was concealed from participants, nurses, and investigators. Primary endpoints were frequency and severity of injection-site and systemic reactions within 28 days of each vaccination. Secondary endpoints were the immunogenicity of DENVax against all four dengue virus serotypes, and the viraemia due to each of the four vaccine components after immunisation. Analysis was by intention to treat for safety and per protocol for immunogenicity. Because of the small sample size, no detailed comparison of adverse event rates were warranted. The trial is registered with ClinicalTrials.gov, number NCT01224639. Findings We randomly assigned 96 patients to one of the four study groups: 40 participants (42%) received low-dose vaccine and eight participants (8%) received placebo in the low-dose groups; 39 participants (41%) received high-dose vaccine, with nine (9%) participants assigned to receive placebo. Both formulations were well tolerated with mostly mild and transient local or systemic reactions. No clinically meaningful differences were recorded in the overall incidence of local and systemic adverse events between patients in the vaccine and placebo groups; 68 (86%) of 79 participants in the vaccine groups had solicited systemic adverse events compared with 13 (76%) of 17 of those in the placebo groups. By contrast, 67 participants (85%) in the vaccine group had local solicited reactions compared with five (29%) participants in the placebo group. Immunisation with either high-dose or low-dose DENVax formulations induced neutralising antibody responses to all four dengue virus serotypes; 30 days after the second dose, 47 (62%) of 76 participants given vaccine seroconverted to all four serotypes and 73 (96%) participants seroconverted to three or more dengue viruses. Infectious DENVax viruses were detected in only ten (25%) of 40 participants in the low-dose group and 13 (33%) of 39 participants in the high-dose group. Interpretation Our findings emphasise the acceptable tolerability and immunogenicity of the tetravalent DENVax formulations in healthy, flavivirus-naive adults. Further clinical testing of DENVax in different age groups and in dengue-endemic areas is warranted. Funding Takeda Vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037
Dengue, Urbanization and Globalization: The Unholy Trinity of the 21st Century
Gubler, D. J. (2011) · Tropical Medicine and Health · doi:10.2149/tmh.2011-s05 · Cited by 1,098
Research works printed but not linked: 47
- Guzman, 2002, Dengue: an update, Lancet Infect Dis, 2, 33, 10.1016/S1473-3099(01)00171-2 · DOI · Paper page
- Wilder-Smith, 2008, Geographic expansion of dengue: the impact of international travel, Med Clin North Am, 92, 1377, 10.1016/j.mcna.2008.07.002 · DOI · Paper page
- Halstead, 2007, Dengue, Lancet, 370, 1644, 10.1016/S0140-6736(07)61687-0 · DOI · Paper page
- Halstead, 2005, Dengue virus: molecular basis of cell entry and pathogenesis, 25–27 June 2003, Vienna, Austria, Vaccine, 23, 849, 10.1016/j.vaccine.2004.03.069 · DOI
- Gibbons, 2007, Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences, Am J Trop Med Hyg, 77, 910, 10.4269/ajtmh.2007.77.910 · DOI · Paper page
- Halstead, 2013, Identifying protective dengue vaccines: guide to mastering an empirical process, Vaccine, 31, 4501, 10.1016/j.vaccine.2013.06.079 · doi:10.1016/j.vaccine.2013.06.079
- Butrapet, 2000, Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3, J Virol, 74, 3011, 10.1128/JVI.74.7.3011-3019.2000 · DOI · Paper page
- Osorio, 2011, Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever, Vaccine, 29, 7251, 10.1016/j.vaccine.2011.07.020 · doi:10.1016/j.vaccine.2011.07.020
- Huang, 2003, Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development, J Virol, 77, 11436, 10.1128/JVI.77.21.11436-11447.2003 · doi:10.1128/jvi.77.21.11436-11447.2003
- Osorio, 2011, Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques, Am J Trop Med Hyg, 84, 978, 10.4269/ajtmh.2011.10-0592 · DOI
- Brewoo, 2012, Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice, Vaccine, 30, 1513, 10.1016/j.vaccine.2011.11.072 · DOI
- Huang, 2013, Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax), PLoS Negl Trop Dis, 7, e2243, 10.1371/journal.pntd.0002243 · DOI
- Huang, 2010, The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion, Virology, 396, 305, 10.1016/j.virol.2009.10.027 · doi:10.1016/j.virol.2009.10.027
- Kitchener, 2006, Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults, Vaccine, 24, 1238, 10.1016/j.vaccine.2005.09.029 · doi:10.1016/j.vaccine.2005.09.029
- Durbin, 2006, The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers, Hum Vaccin, 2, 167, 10.4161/hv.2.4.2944 · doi:10.4161/hv.2.4.2944
- Nguyet, 2013, Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes, Proc Natl Acad Sci USA, 110, 9072, 10.1073/pnas.1303395110 · DOI · Paper page
- Brault, 2011, Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5′ untranslated region and amino acid substitutions in nonstructural proteins 1 and 3, Vector Borne Zoonotic Dis, 11, 683, 10.1089/vbz.2010.0150 · doi:10.1089/vbz.2010.0150
- Sabchareon, 2012, Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial, Lancet, 380, 1559, 10.1016/S0140-6736(12)61428-7 · DOI · Paper page
- Mahalingam, 2013, Call to action for dengue vaccine failure, Emerg Infect Dis, 19, 1335, 10.3201/eid1908.121864 · DOI
- Bhamarapravati, 1987, Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers, Bull World Health Organ, 65, 189
- Bhamarapravati, 1989, Study of bivalent dengue vaccine in volunteers, Lancet, 333, 1077, 10.1016/S0140-6736(89)92471-9 · doi:10.1016/s0140-6736(89)92471-9
- Vaughn, 1996, Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers, Vaccine, 14, 329, 10.1016/0264-410X(95)00167-Y · doi:10.1016/0264-410x(95)00167-y
- Kanesa-thasan, 2001, Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers, Vaccine, 19, 3179, 10.1016/S0264-410X(01)00020-2 · doi:10.1016/s0264-410x(01)00020-2
- Sabchareon, 2002, Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses, Am J Trop Med Hyg, 66, 264, 10.4269/ajtmh.2002.66.264 · doi:10.4269/ajtmh.2002.66.264
- Edelman, 2003, Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine, Am J Trop Med Hyg, 69, 48, 10.4269/ajtmh.2003.69.48 · DOI · Paper page
- Innis, 2003, Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command, Am J Trop Med Hyg, 69, 1, 10.4269/ajtmh.2003.69.6_suppl.0690001 · doi:10.4269/ajtmh.2003.69.6_suppl.0690001
- Sun, 2003, Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates, Am J Trop Med Hyg, 69, 24, 10.4269/ajtmh.2003.69.6_suppl.0690024 · DOI
- Simasathien, 2008, Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children, Am J Trop Med Hyg, 78, 426, 10.4269/ajtmh.2008.78.426 · doi:10.4269/ajtmh.2008.78.426
- Anderson, 2011, Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate, J Infect Dis, 204, 442, 10.1093/infdis/jir279 · DOI
- Watanaveeradej, 2011, Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants, Am J Trop Med Hyg, 85, 341, 10.4269/ajtmh.2011.10-0501 · doi:10.4269/ajtmh.2011.10-0501
- Thomas, 2013, A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults, Am J Trop Med Hyg, 88, 73, 10.4269/ajtmh.2012.12-0361 · doi:10.4269/ajtmh.2012.12-0361
- Durbin, 2010, Dengue vaccine candidates in development, Curr Top Microbiol Immunol, 338, 129
- Poo, 2011, Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity, Pediatr Infect Dis J, 30, e9, 10.1097/INF.0b013e3181fe05af · doi:10.1097/inf.0b013e3181fe05af
- Capeding, 2011, Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase 1 trial in the Philippines, Vaccine, 29, 3863, 10.1016/j.vaccine.2011.03.057 · doi:10.1016/j.vaccine.2011.03.057
- Durbin, 2011, Next-generation dengue vaccines: novel strategies currently under development, Viruses, 3, 1800, 10.3390/v3101800 · doi:10.3390/v3101800
- Lindow, 2012, Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans, PLoS Negl Trop Dis, 6, e1742, 10.1371/journal.pntd.0001742 · DOI
- Bentsi-Enchill, 2013, Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation, Vaccine, 31, 2603, 10.1016/j.vaccine.2013.03.038 · DOI
- Dayan, 2013, Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil, Am J Trop Med Hyg, 89, 1058, 10.4269/ajtmh.13-0304 · doi:10.4269/ajtmh.13-0304
- Dayan, 2013, Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA, Vaccine, 31, 5047, 10.1016/j.vaccine.2013.08.088 · DOI
- Durbin, 2013, A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial, J Infect Dis, 207, 957, 10.1093/infdis/jis936 · doi:10.1093/infdis/jis936
- Lindow, 2013, Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles, Vaccine, 31, 3347, 10.1016/j.vaccine.2013.05.075 · DOI
- Villar, 2013, Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: a randomized, controlled, phase II trial in Latin America, Pediatr Infect Dis J, 32, 1102, 10.1097/INF.0b013e31829b8022 · doi:10.1097/inf.0b013e31829b8022
- Beckett, 2011, Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial, Vaccine, 29, 960, 10.1016/j.vaccine.2010.11.050 · DOI · Paper page
- Bhamarapravati, 2000, Live attenuated tetravalent dengue vaccine, Vaccine, 18, 44, 10.1016/S0264-410X(00)00040-2 · doi:10.1016/s0264-410x(00)00040-2
- Sun, 2009, Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults, Hum Vaccin, 5, 33, 10.4161/hv.5.1.6348 · doi:10.4161/hv.5.1.6348
- Whitehead, 2007, Prospects for a dengue virus vaccine, Nat Rev Microbiol, 5, 518, 10.1038/nrmicro1690 · DOI · Paper page
- Wright, 2009, Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4Δ 30-4995 in healthy adult volunteers, Am J Trop Med Hyg, 81, 834, 10.4269/ajtmh.2009.09-0131 · DOI
Cited by
Guzman, M. G., Gubler, D. J., Izquierdo, A., Martinez, E., & Halstead, S. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.55 · Cited by 762
Bowman, L. R., Donegan, S., & McCall, P. J. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004551 · Cited by 449
Dengue Fever: Causes, Complications, and Vaccine Strategies
Khetarpal, N., & Khanna, I. (2016) · Journal of Immunology Research · doi:10.1155/2016/6803098 · Cited by 363
Biswal, S., Borja-Tabora, C., Martinez Vargas, L., Velásquez, H., Theresa Alera, M., Sierra, V., Johana Rodriguez-Arenales, E., Yu, D., Wickramasinghe, V. P., Duarte Moreira, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30414-1 · Cited by 263
Efficacy and community effectiveness of larvivorous fish for dengue vector control
Han, W. W., Lazaro, A., McCall, P. J., George, L., Runge‐Ranzinger, S., Toledo, J., Velayudhan, R., & Horstick, O. (2015) · Tropical Medicine & International Health · doi:10.1111/tmi.12538 · Cited by 53
Metadata
- Authors
- Osorio, J. E., Velez, I. D., Thomson, C., Lopez, L., Jimenez, A., Haller, A. A., Silengo, S., Scott, J., Boroughs, K. L., Stovall, J. L., Luy, B. E., Arguello, J., Beatty, M. E., Santangelo, J., Gordon, G. S., Huang, C. Y.-H., & Stinchcomb, D. T.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 14
- Issue
- 9
- Pages
- 830-838
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2119735531
- Cited by
- 158
- References
- 2
- FWCI
- 20.22
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. https://app.cochat.ai/papers/10.1016/s1473-3099(14)70811-4
- The paper
- Osorio, J. E., Velez, I. D., Thomson, C., Lopez, L., Jimenez, A., Haller, A. A., Silengo, S., Scott, J., Boroughs, K. L., Stovall, J. L., Luy, B. E., Arguello, J., Beatty, M. E., Santangelo, J., Gordon, G. S., Huang, C. Y.-H., & Stinchcomb, D. T. (2014). Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(14)70811-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.